Three major drugmakers disclosed missed primary endpoints within days of each other in September 2026 — here’s what went wrong, who it affects, and what it signals about pharma R&D.
The Novo Nordisk rebrand introduces the single ‘Novo’ brand name, a ‘Lasting Health Starts Now’ platform, and a new culture framework called The Novo Way, unveiled by CEO Mike Doustdar ahead of the company’s 21 September Capital Markets Day in London.
Novo Nordisk Awiqli, the first FDA-approved once-weekly basal insulin for type 2 diabetes, has launched nationwide across more than 70,000 US pharmacies, cutting basal injections from seven per week to one.
Novo Nordisk has released headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating monthly subcutaneous ziltivekimab in patients with ASCVD, CKD, and elevated systemic inflammation.
Novo Nordisk has filed a federal lawsuit accusing Eli Lilly of running misleading Zepbound and Mounjaro ads that compare outdated, lower doses of Wegovy and Ozempic — omitting newer, FDA-approved higher-strength options.
Following a rejected $25 million extortion attempt, a cybercriminal group claims to have stolen 1.3 terabytes of sensitive data in a sophisticated Novo Nordisk cyber attack targeting proprietary drug files and AI systems.
Novo Nordisk A/S has confirmed an IT security breach involving unauthorized access to limited internal systems and data exfiltration. Core operations remain unaffected.
At the ADA 2026 Scientific Sessions, Novo Nordisk unveiled Phase 2 data for zenagamtide (amycretin), demonstrating exceptional blood sugar control and weight loss in type 2 diabetes.
Novo Nordisk has expanded global access to obesity care by launching the once-daily Wegovy pill in the United Arab Emirates, offering a non-injectable alternative with a 17% mean weight loss and MACE risk reduction.
New results from the POSEIDON study presented at the 94th EAS Congress highlight that cardiovascular inflammation risk persists in 40% of high-risk patients, signaling an urgent need for targeted therapies.
